GlaxoSmithKline, Sanofi, Others See Zantac Cancer Claims Advance

July 1, 2021, 6:38 PM

GlaxoSmithKline LLC and other makers of branded Zantac products must keep defending against personal injury claims in litigation alleging the once-popular antacids cause cancer, following a series of rulings by a federal court in Florida.

Plaintiffs allege ranitidine, the active ingredient in Zantac and its generic equivalents, is unstable and breaks down into NDMA, a probable human carcinogen.

About 1,400 plaintiffs have filed personal injury lawsuits alleging years of prescription and over-the-counter antacid use caused cancer. Additionally, about 100,000 plaintiffs have registered claims with the court.

Those lawsuits, and proposed class actions seeking refunds and medical monitoring, are proceeding in ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.